

# Distinct Pharmacodynamic Activity of Rilpivirine in Mucosal Explant Tissue

Charlene S. Dezzutti, PhD<sup>1,2</sup>, Laura J. Else, PhD<sup>3</sup>, Sarah E. Yandura<sup>2</sup>, Cory Shetler<sup>2</sup>, Julie Russo<sup>2</sup>, David J. Back, PhD<sup>3</sup>, and Ian McGowan, MD, PhD<sup>1,2</sup>  
<sup>1</sup>School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA, <sup>2</sup>Magee-Womens Research Institute, Pittsburgh, PA, USA, <sup>3</sup>Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, UK

Charlene S. Dezzutti, PhD  
 University of Pittsburgh  
 Magee-Womens Research Institute  
 204 Craft Avenue  
 Pittsburgh PA, 15213  
 Voice 412-641-3462  
 Fax 412-641-6170  
 cdezzutti@mrwi.magee.edu

## Introduction


- Rilpivirine (RPV) is a potent, second generation nonnucleoside reverse transcriptase inhibitor.
- A long-acting (LA) formulation has been developed for treatment and is being considered for HIV prevention.
- Two dose escalation clinical trials have been completed in men and women.
  - SSAT040 evaluated 300 mg, 600 mg, and 1200 mg of RPV LA; men were dosed with 600 mg only.
  - MWRI-01 evaluated 600 mg and 1200 mg of RPV LA and incorporated the *ex vivo* challenge assay.
- Drug penetration into rectal tissue (93 and 78 ng/ml) was approximately twice as much as compared to vaginal tissue (38 and 39 ng/ml) in both studies for the 600 mg dose.
- Significant suppression of HIV infection was noted 1 month post-injection for rectal tissue, but not for cervical or vaginal tissue (*ex vivo* challenge assay) in participants receiving the 600 and 1200 mg doses in MWRI-01.
- Our interest was to define the concentration of RPV (pharmacokinetics [PK]) needed to prevent HIV infection (pharmacodynamics [PD]) in mucosal tissue.

## Methods

- RPV was supplied by Janssen Pharmaceutica, Belgium.
- HIV-1<sub>BaL</sub> was used for the experiments here and is the same virus used for the *ex vivo* challenge assay in MWRI-01. The 50% tissue culture infectious dose (TCID<sub>50</sub>) was determined in peripheral blood mononuclear cells.
- The *in vitro* 90% effective concentration (EC<sub>90</sub>) and 90% cytotoxic concentration (CC<sub>90</sub>) of RPV for HIV-1<sub>BaL</sub> was determined by the 4-parameter Emax model [ $y = \min + (\max - \min) / (1 + (x/EC_{90})^{-HillSlope})$ ] (SigmaPlot11, Systat Software, Inc., San Jose, CA) using TZM-bl assay data.
- For drug efficacy, 10-fold dilutions of RPV were applied to the basolateral chamber of polarized tissue explants for 24 h followed by infection with HIV-1<sub>BaL</sub> (5 × 10<sup>4</sup> TCID<sub>50</sub> for ectocervical tissue and 10<sup>4</sup> TCID<sub>50</sub> colonic tissue) added to the apical surface for an additional 24 h. The explants were washed and supernatant was collected and replenished every 3-4 days for 21 days. HIV infection was measured in the supernatants by HIV p24 ELISA.
- In some experiments, explants were set-up in quadruplicate and the second set of explants were collected after 48 h of culture for drug quantification using a validated LC-MS/MS method. Rilpivirine concentrations below the level of quantification (BLQ) were imputed to half the lower limit of quantification (LOQ).
- Correlations between log<sub>10</sub> transformed p24 levels on day 21 and log<sub>10</sub> transformed drug levels were defined by GraphPad Prism® (V5.02) software (La Jolla, CA) using a linear, least-squared regression where the probability value of the slope indicated a relationship that was significantly different to the zero slope (P < 0.05). To define the tissue effective dose, the % inhibition was calculated for each explant based on setting the untreated control day 21 p24 as 100% infected. Using the 4-parameter Emax model, the EC<sub>90</sub> was calculated.


## Acknowledgement

This work was supported by a grant from the Bill and Melinda Gates Foundation, #OPP1045325.



**Figure 1. *In vitro* EC<sub>90</sub> and CC<sub>90</sub> of RPV.** The EC<sub>90</sub> was 1.67 nM and the CC<sub>90</sub> was 5827 nM. RPV is a potent, non-toxic drug.

**Figure 2. Efficacy of RPV in polarized ectocervical and colonic tissue explants.**



- Viral replication was suppressed in the ectocervical tissue explants dosed with 10 μM of RPV and in colonic tissue explants dosed with 1 μM of RPV as compared to HIV-1 only controls (**Figure 2; Table 1**).
- Lower concentrations of RPV added to the basolateral medium showed partial inhibition with loss at 0.01 μM for both tissue types (**Figure 2; Table 1**).

**Table 1. Inhibition of HIV in ectocervical and colonic tissue explants treated with basolateral RPV.**

[RPV] <sup>a</sup>	Ectocervical explants		Colonic explants	
	# protected / # tested	% inhibition <sup>b</sup>	# protected / # tested	% inhibition <sup>b</sup>
10 μM	10 / 10	98%	9 / 9	99.8%
1 μM	7 / 12	98%	15 / 15	99.8%
0.1 μM	2 / 10	62%	11 / 15	99.7%
0.01 μM	0 / 6	59%	2 / 8	31.0%

<sup>a</sup>Concentration of RPV added to the basolateral supernatant.

<sup>b</sup>% inhibition was calculated using averaged median p24 values from day 21 of culture shown in Fig 2.

## References

- Jackson AG, Else LJ, Mesquita PM, Egan D, Back DJ, Karolia Z, Ringner-Nackter L, Higgs CJ, Herold BC, Gazzard BG, Boffito M. 2014. A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. *Clin Pharmacol Ther* 96:314-323.
- McGowan, CS Dezzutti, A Siegel, J Engstrom, A Nikiforov, K Duffill, C Shetler, N Richardson-Harman, K Abebe, D Back, L Else, D Egan, S Khoo, J Egan, R Stall, P Williams, KK Rehman, A Adler, R Brand, R D Cranston. 2016. A Compartmental Pharmacokinetic and Pharmacodynamic Assessment of Rilpivirine Long-Acting Pre-Exposure Prophylaxis in HIV-Negative Volunteers. *Lancet HIV* In submission
- Azjin H, Tirry I, Vingerhoets J, de Bethune MP, Kraus G, Boven K, Jochmans D, Van Craenenbroeck E, Picchio G, Rimsky LT. 2010. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. *Antimicrob Agents Chemother* 54:718-727.
- Dezzutti CS, Else LJ, Yandura SE, Shetler C, Russo J, Back DJ, McGowan I. 2016. Distinct pharmacodynamic activity of rilpivirine in ectocervical and colonic explant tissue. *Antimicrob Agents Chemother* In submission.


## Results

**Table 2. RPV concentration in ectocervical and colonic tissue explants.**

[RPV] added to culture	Ectocervical explants		Colonic explants	
	[RPV] (mean ± SD)	%RPV in tissue <sup>a</sup>	[RPV] (mean ± SD)	%RPV in tissue <sup>a</sup>
10 μM	282 ± 116 ng/mL	8%	4624 ± 1745 ng/mL	126%
1 μM	20 ± 11 ng/mL	6%	467 ± 103 ng/mL	128%
0.1 μM	BLQ	—	47 ± 10 ng/mL	127%
0.01 μM	BLQ	—	3.4 ± 1.2 ng/mL	100%

[RPV], Rilpivirine concentration; BLQ, below limit of quantification

<sup>a</sup>Relative tissue concentration as a percentage of the total amount of RPV added to the culture.



**Figure 3. PK and PD activity of RPV modeled in mucosal tissue.**

- Data BLQ were imputed as ½ LOQ (0.6 log<sub>10</sub> ng/mL) and indicated with a vertical dotted line.
- RPV tissue concentrations (log<sub>10</sub> ng/mL) were plotted against day 21 p24 log<sub>10</sub> pg/mL with significance noted for ectocervical (**a**) and colonic (**c**) explants.
- Dose response relationship between [RPV] and % inhibition defined the EC<sub>90</sub> for ectocervical (99 ng/mL; 271 nM) (**b**) and colonic (16.33 ng/mL 45 nM) (**d**) explants.

## Conclusions

- RPV was effective *in vitro* against HIV-1<sub>BaL</sub> as measured in TZM-bl and mucosal tissue assays.
- RPV penetrated colonic tissue better than ectocervical tissue by >10-fold *in vitro*, which was consistent with the PK data from the two clinical trials.
- SSAT040 (600 mg) and MWRI-01 (600 mg) studies demonstrated similar concentrations of RPV in rectal (93 and 78 ng/ml) and vaginal (39 and 38 ng/ml) tissues.
- Importantly, the data presented here suggest that the concentrations of RPV in the rectal tissue exceeded by ~5-fold what would be needed to suppress viral infection (>16 ng/ml), but was 2.5-fold below the suppressive levels needed in cervical / vaginal tissue (>99 ng/ml).
- This was confirmed by the *ex vivo* challenge data from MWRI-01; HIV infection was suppressed in rectal tissue but not in cervical / vaginal tissues.
- Our data suggest that after parenteral dosing, sufficient levels of RPV appear to be present in the colon, but higher concentrations may be needed in the cervix / vagina for protection against HIV acquisition.